title: Bortezomib-based treatment for relapsed and refractory angioimmunoblastic T-cell lymphoma: Case report and literature review.
abstract: Angioimmunoblastic T-cell lymphoma (AITL) is a distinct peripheral T-cell lymphoma (PTCL) subtype, accounting for 15-20% of PTCL and 2% of all non-Hodgkin lymphoma (NHL), with a poor prognosis. In the present study, we describe a 76-year-old patient with AITL who failed to respond to conventional chemotherapy but responded to bortezomib-based treatment and demonstrated persistent clinical improvement at the 18-month follow-up. These data suggest that bortezomib-based treatment may be a reliable, safe and effective alternative for treating relapsed/refractory AITL.
authors: Department of Hematology, Shanghai Changzheng Hospital, The Second Military Medical University, Shanghai 200003, P.R. China.
authors: Shuyan
authors: S
authors: Liu
authors: Zhengang
authors: Z
authors: Yuan
authors: Chunyang
authors: C
authors: Zhang
authors: Weijun
authors: W
authors: Fu
authors: Jian
authors: J
authors: Hou